Clinical trials: Asymptomatic COVID-19
Covid19
Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.
MAD0004J08, the experimental drug, is a potent neutralizing IgG1 monoclonal antibody (mAb) targeting the spike protein of SARS-CoV-2. MAD0004J08 blocks viral attachment and entry into human cells and neutralizes the virus.
- Trial name
- NCT04952805
- Testing
- MAD0004J08
- Where
- 14 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
COVID-19
Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study
This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects…
- Trial name
- NCT05373446
- Testing
- SSD8432 300mg, SSD8432 750mg
- Volunteers
- 72 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
SARS-CoV-2 Infection (Asymptomatic), SARS-CoV-2 Infection (Symptomatic)
COVID-19 Progression in End-Stage Kidney Disease
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
- Trial name
- COPE (NCT04495907)
- Where
- 11 sites in United States
- Volunteers
- 412 people
- Sponsor
- Davita Clinical Research